Introduction
Transforming growth factor-b1 (TGF-b1) is a member of a large family of multifunctional polypeptides that play a fundamental role in cell regulation (Massague, 1990) . TGF-b1 signal is transduced from plasma membrane to the nucleus via heteromeric complex of serine/threonine kinase receptor type I (TbR-I) and type II (TbR-II) and their downstream effectors Smads (Heldin et al., 1997) . Upon ligand binding, TbR-II phosphorylates and activates TbR-I, which directly phosphorylates the receptor-regulated R-Smads (Smad2 and Smad3), which then form a hetero-oligomer with Co-Smad (Smad4). These complexes translocate into the nucleus, where they regulate transcription of TGF-b1-responsive genes.
TGF-b1 acts as a potent growth inhibitor in cells of the epithelial lineage and the TGF-b1 signaling pathway is disrupted in a number of human carcinomas by mutational alterations of its receptors or Smads (Markowitz et al., 1995; Riggins et al., 1997) . In the prostate, TGF-b1 inhibits growth of carcinoma and normal epithelial cells, and aberrant function of TbR-I and TbR-II correlates with tumor aggressiveness (Kim et al., 1996 (Kim et al., , 1998 Williams et al., 1996) . However, both intracellular and serum TGF-b1 levels are elevated in prostate cancer patients and further increased in patients with metastatic carcinoma (Truong et al., 1993; Eastham et al., 1995) . Previous studies also showed that prostate cancer cells are resistant to TGF-b1-induced growth inhibition and TGF-b1 actually promotes tumor growth, angiogenesis, and metastasis, suggesting that TGF-b1 action is oncogenically conversed in the process of tumorigenesis (Sehgal et al., 1996; Barrack, 1997; Stearns et al., 1999) . Consistent with these reports, we recently identified that TGF-b1 stimulates prostate tumor cell proliferation through the Ha-Ras-mediated activation of the mitogen-activated protein kinase (MAPK) signaling pathway, which suggests that prostate carcinomas with Ras/MAPK activation might have a selective growth advantage by autocrine TGF-b1 production (Park et al., 2000) .
Interleukin-6 (IL-6) is a pleiotropic cytokine that plays a central role in antigen-specific immune responses and inflammatory reactions . In addition, IL-6 has been implicated in the pathology of a variety of malignant tumors including myeloma, renal cell carcinoma, and cervical carcinoma (Miki et al., 1989; Akira and Kishimoto, 1992; Eustace et al., 1993) . IL-6 expression is upregulated in several solid and hematopoietic neoplasms and elevated levels of circulating IL-6 have been reported to be associated with poor outcome of the diseases (Miki et al., 1989; Akira and Kishimoto, 1992; Eustace et al., 1993; Oka et al., 1996; Seymour et al., 1997) Autocrine growth stimulation and/or apoptosis inhibition via phosphoinositide-3-kinase (PI3K) activation have been suggested as the possible mechanisms for the oncogenic action of IL-6 (Miki et al., 1989; Akira and Kishimoto, 1992; Eustace et al., 1993) . In the prostate, high levels of IL-6 secretion were found in the sera of patients with metastatic prostate carcinoma, and increased serum IL-6 levels correlate with hormone-refractory disease and cancer morbidity (Twillie et al., 1995; Adler et al., 1999; Drachenberg et al., 1999) . IL-6 is expressed in carcinoma and benign prostatic hyperplasia tissues, and IL-6R mRNA is detected in all prostate carcinoma cell lines tested but not in normal epithelial cells or stromal cells derived from benign prostatic hyperplasia (BPH), suggesting that IL-6 functions as autocrine or paracrine growth factor for prostate carcinoma (Siegsmund et al., 1994; Okamoto et al., 1997) . Furthermore, prostate cancer cells preferentially spread to IL-6-abundant organs, such as bones, lymph nodes, and lungs, suggesting a crucial role of IL-6 in the pathogenesis of prostate carcinoma (Siegall et al., 1990) . Endogenous IL-6 was identified as a resistant factor for some chemotherapeutic agents such as cis-diamminedichloroplatinum and etoposide in prostate carcinoma cells (Borsellino et al., 1995) . Recently, it was reported that IL-6 protein concentrations are increased approximately 18-fold in clinically localized prostate cancers when compared to normal prostate tissues, and IL-6 acts as a significant autocrine growth factor in vivo for primary, androgen-dependent cancers (Giri et al., 2001) . In addition, IL-6 was identified to inhibit apoptosis through PI3 K activation and promote neuroendocrine differentiation, an early marker for development of androgen independence, of prostate cancer cells (Qiu et al., 1998b; Chung et al., 2000; Deeble et al., 2001) .
Despite a significant role of IL-6 in tumorigenesis, the signaling mechanisms by which IL-6 expression is activated in human tumors have been poorly understood. Recently, TGF-b1 was suggested as a potent regulator of IL-6 in human lung fibroblast and osteoblast (Eickelberg et al., 1999; Franchimont et al., 2000) . It was also reported that both IL-6 and TGF-b1 levels are elevated in patients with metastatic prostatic carcinoma and correlate with tumor burden as assessed by increasing serum PSA or clinically evident metastases (Adler et al., 1999) . To define the molecular basis of IL-6 elevation in human prostate cancer, we investigated the TGF-b1 effect on IL-6 expression. Here, we demonstrate first that the IL-6 gene expression is activated by tumor-producing TGF-b1 in prostate cancer cells. Our data show that TGF-b1 stimulates IL-6 expression through the Smad2 signaling cascade and via the synergistic collaboration of multiple pathways including p38, nuclear factor-kB (NF-kB), stress-activated protein kinases/c-Jun N-terminal kinase (SAPK/JNK), and HaRas. Our study also suggests that elevated IL-6 plays an important role for the oncogenic conversion of TGF-b1 in prostate tumorigenesis, in part by counteracting the growth suppression effect of TGF-b1.
Results

TGF-b1 activates IL-6 expression in prostate carcinoma cells
To explore the interrelation between TGF-b1 and IL-6 in prostate tumorigenesis, we initially examined the expression status of IL-6 and TGF-b1 in four prostate carcinoma cell lines (LNCaP, PC3, DU145, and TSUPr1). As shown in Figure 1a , IL-6 mRNA is expressed in three TGF-b1-producing cell lines (PC3, DU145, and TSU-Pr1) but not in a TGF-b1-nonproducing cell line (LNCaP). Expression levels of IL-6 mRNA in the three cell lines correlated with secreted protein levels of IL-6 (254721, 104717, and 263722 pg/ml/1 Â 10 4 cells in PC3, DU145, and TSU-Pr1, respectively). TGF-b1 treatment increased both IL-6 mRNA and secreted protein levels in DU145 and PC3 in a dose-and timedependent manner, whereas no effect was observed in LNCaP which has a structural alteration of TbR-I (Figure 1b and c) . In DU145 cells, induction of IL-6 mRNA expression was clearly detectable at 3 h after TGF-b1 treatment (2 ng/ml) by Northern blot analysis (Figure 1d ). Moreover, both basal and TGFb1-induced IL-6 secretion were downregulated by anti-TGF-b1 neutralizing antibody (TGF-b1 nAb) in a dose-dependent manner (Figure 1c) . Together, these findings indicate that tumor cell-producing TGF-b1 acts as an IL-6 inducer in human prostate carcinoma cells.
To investigate whether elevated IL-6 expression following TGF-b1 treatment is associated with increased IL-6 gene transcription, we examined effect of actinomycin D treatment on the TGF-b1 induction of IL-6 in DU145 cells. As shown in Figure 2a and b, induction of IL-6 expression by TGF-b1 was markedly suppressed by actinomycin D at both mRNA and secreted protein levels, indicating that IL-6 activation by TGF-b1 requires de novo RNA synthesis. However, it Figure 1 Induction of IL-6 expression by TGF-b1 in prostate carcinoma cells. (a) Expression status of TGF-b1, TbR-I, IL-6, and IL-6R transcripts in four prostate carcinoma cell lines was evaluated by semiquantitative RT-PCR using exon-specific primers. GAPDH was used as an endogenous expression standard. (b) Dose-and time-dependent regulation of IL-6 mRNA expression by TGF-b1 and TGF-b1 neutralizing antibody (TGF-b1 nAb). (c) Effect of TGF-b1 and TGF-b1 nAb on expression of secreted IL-6 protein. Level of secreted IL-6 protein was analysed using ELISA. The data are the means and standard deviations of triplicate determinations. (d) Northern blot analysis of IL-6 mRNA expression in TGF-b1-treated DU145 cells TGF-b1-mediated IL-6 activation in human prostate cancer J-I Park et al was also recognized that TGF-b1 treatment led to a slight but detectable increase in IL-6 expression level in the presence of actinomycin D, whereas mRNA expression of PAI-I, a representative transcription target of TGF-b1, was completely inhibited by actinomycin D (Figure 2b ). Meanwhile, TGF-b1-induced IL-6 expression was totally prevented by cyclohexamide, indicating that de novo protein synthesis is required for TGF-b1 regulation of IL-6 expression. To further define whether TGF-b1 modifies the mRNA stability of IL-6 in prostate cancer cells, mRNA decay level of IL-6 was compared between TGF-b1-treated and -untreated cells using Northern blot assay. A time course of IL-6 mRNA decay revealed that in the presence of actinomycin D, the mRNA stability of IL-6 is modestly increased following TGF-b1 treatment (Figure 2c ). The time required for a 50% loss of IL-6 mRNA increased from 4.5 to 8 h by TGF-b1. Collectively, these results show that TGF-b1 activation of IL-6 occurs predominantly at the transcriptional level, but is also achieved partially through the post-transcriptional mechanisms.
TGF-b1-mediated IL-6 induction occurs through the Smad2 signaling pathway
To characterize the signaling mechanisms by which TGF-b1 activates IL-6 expression, we transfected PC3 and DU145 cells with DN mutants of TbR-II, Smad2, and Smad3. The DN mutants for TbR-II and Smad2/3 were generated by deletion of a kinase domain of TbR-II and by replacing three serine residues by alanines at COOH-terminal SSXS motif of Smad2/3, respectively (Park et al., 2000) . Protein expression of these DN mutants in transfected cells was verified using Western blot and immunofluorescence microscopic assays, and their inhibitory function was indicated by suppression of TGF-b1-induced phosphorylation and nuclear translocation of endogenous Smad2/3 by DN-TbRII and DNSmad2/3, respectively (data not shown). As shown in PC3 and DU145 cells were transiently transfected with expression plasmids encoding DN-TbRII, DN-Smad2, DN-Smad3, WTSmad2, and WT-Smad3. TGF-b1 (2 ng/ml) was treated for 24 h and its effect on IL-6 and IL-6R mRNA expression was analysed by semiquantitative RT-PCR. p38 MAPK is activated by TGF-b1 and involved in IL-6 induction by TGF-b1
It has been documented that IL-6 activation by IL-1b or TNF-a is mediated through the p38 MAPK pathway, and p38 MAPK participates in TGF-b1-induced gene expression (Hanafusa et al., 1999; Craig et al., 2000; Wery-Zennaro et al., 2000) . Based on these reports, we explored whether the p38 MAPK signaling is involved in the TGF-b1-induced IL-6 expression in prostate cancer cells. As shown in Figure 4a , phosphorylation of p38 MAPK was significantly increased following TGF-b1 treatment in PC3 and DU145 cells. Moreover, pretreatment with the p38 inhibitor SB202190 or SB203580 led to a profound inhibition of TGF-b1-induced IL-6 expression, indicating a crucial role for p38 MAPK in IL-6 activation by TGF-b1 (Figure 4b and c). It was reported that TGF-b1 induces the phosphorylation of ATF2 through the p38 MAPK cascade, and phosphorylated ATF2 could associate with Smad4 and activate transcription of TGF-b1-responsive genes (Hanafusa et al., 1999) . In addition, PDGF was found to activate IL-6 gene transcription in osteoblasts by regulating ATF2 (Franchimont et al., 1999) . To elucidate the possible implication of ATF2 activation in TGF-b1-induced IL-6 expression, we examined whether phosphorylation of ATF2 is stimulated in TGF-b1-treated prostate cancer cells. However, our immunoblotting assay using a phosphospecific ATF2 antibody demonstrated that phosphorylation of ATF2 is not affected by TGF-b1 treatment whereas it is significantly increased by osmotic stress using NaCl (Figure 4d ). These results indicate that p38 MAPK but not ATF2 plays an important role in the TGF-b1-induced IL-6 expression in prostate carcinoma cells.
NF-kB is activated by p38 MAPK and required for TGF-b1-mediated IL-6 induction NF-kB is a key regulatory factor for IL-6 gene transcription and its activation by various cytokines occurs through p38 MAPK in many types of human cells (Asschert et al., 1999; Craig et al., 2000) . To evaluate the involvement of NF-kB activation in TGFb1-mediated IL-6 induction, we examined whether TGF-b1 stimulates nuclear translocation of NF-kB.
Immunoblotting assay for nuclear and cytoplasmic fractions of DU145 cells revealed that nuclear level of NF-kB/p65 is dramatically increased at 20 min after TGF-b1 treatment ( Figure 5a ). Nuclear translocation of NF-kB was also detected by immunofluorescence microscopic analysis (data not shown). To elicit NFkB role for IL-6 induction, NF-kB activation was blocked by transfection of the phosphorylation-deficient, DN mutant of IkB (IkBDN), which protects degradative loss of IkB, or by treatment of the proteosome inhibitor MG132 (Brockman et al., 1995) . As shown in Figure 5b and c, transient transfection of IkBDN or treatment of MG132 resulted in a strong inhibition of TGF-b1-induced IL-6 expression at both mRNA and secreted protein levels. Furthermore, TGFb1-induced nuclear translocation of NF-kB was completely inhibited by pretreatment of SB202190 or SB203580 whereas no visible effect was recognized by pretreatment of the MEK1 inhibitor PD98059 (Figure 5d ). Collectively, these findings indicate that TGF-b1 activates NF-kB through p38 MAPK in prostate cancer cells, and the p38-NF-kB signaling cascade plays a critical role for the TGF-b1-mediated IL-6 activation.
C-Jun activation by SAPK/JNK mediates IL-6 induction by TGF-b1
AP-1 plays a key role in IL-6 induction by various cytokines and c-Jun activates many AP-1-containing target genes (Asschert et al., 1999; Franchimont et al., 1999) . Recently, Smad3 and Smad4 were identified to interact with c-Jun that is rapidly phosphorylated in response to TGF-b1 (Krause et al., 1998; Liberati et al., 1999) . Consistent with these reports, in PC3 and DU145 cells, c-Jun phosphorylation was evident at 6-12 h after TGF-b1 treatment ( Figure The Ras-Raf1-MEK1 pathway participates in TGF-b1 induction of IL-6 via AP-1
To further investigate the possible involvement of other signaling pathways in IL-6 activation by TGF-b1, we examined effect of various phamarcological inhibitors on IL-6 expression. As shown in Figure 7a , TGF-b1-mediated IL-6 induction was inhibited by the MEK1 inhibitor PD98059 but not altered by the PI3 K inhibitor wortmannin or LY294002, the Src inhibitor PP2, and the protein tyrosine kinase inhibitor Genistein. We then asked whether the Ras-MAPK pathway is involved in TGF-b1-induced IL-6 expression. As predicted, TGF-b1 treatment led to a detectable increase of Erk1/2 phosphorylation, and blocking the Ras-Raf-1-MEK1 cascade by transfection of DN-Ha-Ras (N17Ha-Ras) or DN-Raf-1 suppressed the TGF-b1 effect on Erk1/2 phosphorylation, whereas transient expression of oncogenic V12Ha-Ras strongly increased Erk1/2 phosphorylation ( Figure 7b ). Furthermore, whereas IL-6 expression was hindered by N17Ha-Ras or DN-Raf-1, it was further activated by V12Ha-Ras in the presence or absence of TGF-b1 (Figure 7c and d). Meanwhile, IL-6-enhancing effect of V12Ha-Ras was severely impeded by curcumin treatment, indicating that IL-6 induction by the Ha-Ras signaling is mediated through AP-1 Figure 4 Involvement of p38 MAPK in TGF-b1-mediated IL-6 induction. (a) Induction of p38 phosphorylation by TGF-b1. PC3 and DU145 cells were treated with TGF-b1 (2 ng/ml) and phosphorylation of p38 was examined by Western blot assay using a phosphospecific p38 antibody and chemiluminescence detection. (b) Effect of p38 inhibitors on TGF-b1-induced IL-6 mRNA expression. The cells were incubated with the p38 inhibitor SB202190 (10 mm) or SB203580 (10 mm) for 2 h before TGF-b1 treatment (2 ng/ml, 24 h). Expression of IL-6 mRNA was examined by Northern blot assay. (c) Inhibition of TGF-b1-induced IL-6 protein expression by SB202190 and SB203580. Expression level of secreted IL-6 protein was analysed using ELISA. Data represent means of triplicate assays. bars; standard deviations (d) No detectable effect of TGF-b1 on ATF2 phosphorylation. DU145 cells were treated with TGF-b1 (2 ng/ml) and phosphorylation of ATF2 was determined by Western blot assay using a phsophospecific ATF2 antibody. Cells were exposed to osmotic stress using NaCl (250 mm) as a control for ATF2 phosphorylation TGF-b1-mediated IL-6 activation in human prostate cancer J-I Park et al activation ( Figure 7d ). Additionally, it was found that mRNA expression level of c-Jun is significantly enhanced by TGF-b1 and this effect is abolished when the Ras-Raf-1-MEK1 signaling is inhibited. Consistent with this finding, expression of c-Jun mRNA was activated by V12Ha-Ras transfection in the absence of TGF-b1 treatment. However, unlikely mRNA expression, increased phosphorylation of c-Jun by TGF-b1 was not detectably altered by N17Ha-Ras, DN-Raf-1, or PD98059 (Figure 7e ). Collectively, these data demonstrate that the Ras-Raf-1-MEK1-Erk1/2 pathway contributes to the TGF-b1 induction of IL-6 in an AP-1-dependent manner in human prostate cancer cells.
Synergistic collaboration of Smad2, NF-kB, and c-Jun in IL-6 activation
Our results demonstrate that multiple signaling pathways including Smad2, p38-NF-kB, SAPK/JNK, and Ras-Raf-1-MEK1 are implicated in the TGF-b1 activation of IL-6 expression in prostate carcinoma cells. It has been known that Smad2/Smad4 complex interacts with many TGF-b1 target gene promoters through transcriptional factors or coactivators including AP-1 . Therefore, it is conceivable that TGF-b1 activation of IL-6 gene expression occurs through the collaboration of Smad2, NF-kB, and AP-1 on the IL-6 promoter. As summarized in Figure 8a , our cotransfection assay showed that DN-Smad2, IkBDN, TAM-67, and N17Ha-Ras transfection results in approximately 72, 77, 83, and 65% inhibition of TGF-b1-induced IL-6 expression, respectively, whereas nearly complete inhibition is achieved by cotransfection. Similarly, treatment of SB202190 and PD98059 led to about 82 and 74% inhibition of IL-6, respectively, whereas a combined treatment resulted in more than 95% suppression (data not shown). Furthermore, IL-6 induction by WT-Smad2 was strongly hindered by IkBDN, TAM-67, curcumin, or MG132, and to a lesser extent by SB202190 or PD98059 ( Figure 8b ). As summarized in Figure 9 , all these findings thus indicate that TGF-b1 activation of IL-6 in prostate cancer cells results from the synergistic collaboration of the Smad2, p38-NF-kB, SAPK/JNK, and Ras-Raf-1-MEK1 signaling pathways.
Elevated IL-6 interferes with TGF-b1-induced growth arrest and apoptosis
To investigate whether elevated IL-6 could modulate cellular response to TGF-b1, we treated PC3 and DU145 cells with anti-IL-6 neutralizing antibody (IL-6 nAb) and its effect on TGF-b1-induced cell cycle arrest was analysed using [ 3 H]thymidine uptake assay. Compared to untreated controls, DNA synthesis of the IL-6 nAb-treated cells was more severely inhibited by TGFb1 (Figure 10a ). Although its effect was less significant than IL-6 nAb, antisense IL-6 transfection also led to enhanced response to TGF-b1 (data not shown). PC3 and DU145 cells have WT TbR-I, TbR-II, and Smads but are resistant to TGF-b1-induced apoptosis (Park et al., 2000) . To determine whether IL-6 activation by TGF-b1 confers the resistance to TGF-b1-induced apoptosis, IL-6 nAb effect on apoptosis was examined using tryphan blue exclusion assay. Whereas TGF-b1 or IL-6 nAb alone did not affect apoptosis, TGF-b1 treatment increased apoptotic cell death in a dosedependent manner in the presence of IL-6 nAb ( Figure 10b ). The identical results were observed from [
3 H]thymidine release and Annexin V analyses (data not shown). These findings indicate that elevated expression of IL-6 by TGF-b1 counteracts the growth suppression effect of TGF-b1 and thus could be a resistance factor to TGF-b1 in malignant prostate carcinomas.
Discussion
TGF-b1 plays biphasic functions in prostate tumorigenesis, having a growth inhibitory effect at early stages, but at later stages enhancing the malignant properties of tumors (Truong et al., 1993; Eastham et al., 1995; Kim et al., 1996 Kim et al., , 1998 Sehgal et al., 1996; Williams et al., 1996; Barrack, 1997; Stearns et al., 1999) . However, the molecular mechanism by which TGF-b1 exerts its tumor-promoting effect is not well elucidated. Recently, we reported that TGF-b1 effect could be mitogenically switched by oncogenic Ha-Ras in prostate carcinoma cells (Park et al., 2000) . In the present study, we demonstrate that IL-6, which accelerates proliferation and survival of tumor cells, is activated by TGF-b1 in human prostate cancer cells. Our data show that TGFb1 induces IL-6 expression through the synergistic collaboration of multiple signaling pathways including the Smad2, p38-NF-kB, SAPK/JNK, and Ras-Raf-1-MEK1 cascades. In addition, IL-6 was found to impinge on TGF-b1-induced growth inhibition and apoptosis, suggesting that elevated IL-6 production by tumor-producing TGF-b1 might counteract the tumor suppressive effect of TGF-b1 and thus contribute to the oncogenic conversion of TGF-b1 function in the malignant progression of human prostate carcinomas.
IL-6 expression is controlled by a variety of cytokines including TNF-a and PDGF, and consensus sequences for several known transcriptional factors such as AP-1, CAAT enhancer-binding protein, and NF-kB are present in the IL-6 promoter (Asschert et al., 1999; Berghe et al., 1999; Franchimont et al., 1999; Liberati et al., 1999) . In a different cell culture model, TGF-b1 has been reported to induce IL-6 expression (Mazzarelli et al., 1998; Eickelberg et al., 1999; Franchimont et al., 2000) . In human lung fibroblast cells, TGF-b1 stimulates IL-6 expression, and activation of H 2 O 2 production, Ca + influx, MAPK, and AP-1 mediate the TGF-b1 effect (Chen et al., 1996; Junn et al., 2000) . In the present study, we demonstrate first that in human prostate cancer cells, IL-6 expression is activated by tumorproducing TGF-b1 in a Smad2-dependent manner. In addition, our observation that IL-6 activation by WTSmad2 is severely impeded by blocking the p38-NF-kB, SAPK/JNK, and Ras-Raf-MEK1 signaling cascades, indicating a synergistic collaboration of multiple signaling for the TGF-b1-induced IL-6 expression in prostate cancer cells. Previous studies revealed that Smads control expression of diverse genes through functional cooperation with transcriptional factors or coactivators . The Smad2/Smad4 complex interacts with the Mix.2 and goosecoid promoters through the forkhead transcription factors FAST-1 and FASAT-2, while the Smad3/Smad4 complex binds to specific DNA sequences such as CAGA box present in promoters including PAI-1, JunB, collagen, or Smad7, and interacts with the Jun family of transcription factors and synergistically activates AP-1 promoter sequences (Chen et al., 1996; Labbe et al, 1998; Zhang et al., 1998; Zhou et al., 1998) . It was also demonstrated that Smad2 and Smad3 positively and negatively regulate TGF-b1-dependent transcription through FAST-2, and FAST-1 is able to bind to Smad2 and mediates TGF-b1 response by a DNA-binding complex formed by FAST-1, Smad2, and Smad4 (Labbe et al., 1998; Zhou et al., 1998) . In this study, we found that both basal and TGF-b1-induced IL-6 expressions are up-and downregulated by WT-Smad2 and DN-Smad2, respectively, but not altered by Smad3 transfection, whereas mRNA expression of PAI-1 is significantly affected by transfection of DN-or WT-Smad3, indicating that the Smad3 pathway is not involved in IL-6 activation by TGF-b1. However, we could not identify the FAST-1-binding motif in the IL-6 promoter sequences. Further studies will be required to define whether Smad2 interaction with FAST-1 or FAST-2 is necessary for the transcriptional activation of IL-6 by TGF-b1. It has been reported that TGF-b1 activates the SAPK/JNK pathway, which leads to c-Jun phosphorylation at Ser-63 and Ser-73 that increases its transcriptional activity (Atfi et al., 1997) . Consistent with this report, we found that TGF-b1 induces phosphorylation of c-Jun in PC3 and DU145 cells, and blockade of c-Jun activation leads to a profound inhibition of both TGF-b1-and WT-Smad2-induced IL-6 expression, suggesting that a cooperative interaction of Smad2 and AP-1 might be crucial for the TGF-b1-mediated IL-6 activation in prostate cancer cells.
p38 MAPK plays a key part in IL-6 production by many cytokines including TNF-a, IL-1b, and IL-4 (Miyazawa et al., 1998; Eliopoulos et al., 1999; Wery-Zennaro et al., 2000) . TNF-a-mediated IL-6 induction occurs through TGF-b activating kinase 1 (TAK1) stimulation of NF-kB in which p38 MAPK acts as an activator of IkB kinases (Craig et al., 2000) . TAK1 is a MAPK kinase kinase that can be activated by TGF-b and bone morphogenic protein. Hanafusa et al. (1999) found that TGF-b1 activates TAK1-MKK6-p38 cascade, which leads to the phosphorylation of the transcription factor ATF2, and phosphorylated ATF2 could associate with Smad4 in response to TGF-b1. It was also reported that PDGF activates IL-6 transcription in osteoblasts by regulating AP-1 complex and ATF2 (Franchimont et al., 1999) . It is therefore conceivable that Smad complexes and phosphorylated ATF2 interact in a nucleoprotein complex that associates with DNA and activates transcription of TGF-b1-responsive genes. In prostate cancer cells, we found that TGF-b1 activates NF-kB through p38 MAPK but does not affect ATF2 phosphorylation. TGF-b1-induced IL-6 expression was significantly suppressed by NF-kB inhibition, and pretreatment of p38 inhibitors SB202190 and SB203580 blocked NF-kB activation. However, it should be noted that SB203580 and SB202190 are also able to suppress TGF-b-specific response by interfering with the ATP-binding site of TbR-I (Yakymovych et al., 2002) . Additionally, we identified that inhibitory effect of SB202190 on IL-6 expression is less significant compared to IkBDN or MG132, leading to the conjecture that NF-kB could also be activated by a mechanism(s) distinct from the p38 cascade in TGF-b1-treated prostate cancer cells. Collectively, our data demonstrate that NF-kB activation is critical for the TGF-b1-induced IL-6 expression in human prostate cancer cells.
Numerous studies have provided evidences that TGFb1 activates Ras and Erk, and this activity is essential for many of TGF-b1's actions (Mulder and Morris, 1992) . A crosstalk between the TGF-b1 and Ras-MAPK signaling pathways is implicated in the acquisition of invasive and metastatic potentials of epithelial tumor cells (Oft et al., 1996 (Oft et al., , 1998 Schwarz et al., 1988) . In the present study, we found that the Ras-Raf-1-MEK1 Figure 5 TGF-b1 activation of NF-kB through p38 MAPK in prostate cancer cells. (a) Nuclear translocation of NF-kB following TGF-b1 treatment. Nuclear (N) and cytosolic (C) extracts from TGF-b1-stimulated or -unstimulated DU145 cells were prepared at the indicated time points and NF-kB/p65 was detected by immunoblotting assay using an anti-p65 antibody. U1 SnRNP 70 and b-tubulin were used as a control for purity of nuclear and cytoplasmic extracts, respectively. (b) Inhibition of TGF-b1-induced IL-6 mRNA expression by blocking the NF-kB pathway. PC3 and DU145 cells were transfected with IkBDN or treated with MG132 (0.5 mm). TGFb1 (2 ng/ml) was added for 24 h and IL-6 mRNA expression was examined by Northern blot assay. (c) Suppression of TGF-b1-induced secreted IL-6 protein expression by IkBDN or MG132. Expression levels of secreted IL-6 protein were determined using ELISA. Data represent means of triplicate assays. bars; standard deviation? (d) Abrogation of NF-kB nuclear translocation by p38 inhibitors. DU145 cells were incubated with SB202190 (10 mm), SB203580 (10 mm), or PD98059 (50 mm) for 2 h and then TGF-b1 (2 ng/ml) was treated for 1 h. Cells transfected with IkBDN or treated with MG132 (0.5 mm) were included as controls. NF-kB/p65 was detected by immunoblotting assay using an anti-p65 antibody. U1 SnRNP 70 and b-tubulin were used as a control for purity of nuclear (N) and cytoplasmic (C) extracts, respectively
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TGF-b1-mediated IL-6 activation in human prostate cancer J-I Park et al pathway is activated by TGF-b1 and contributes to the TGF-b1 induction of IL-6 in prostate cancer cells. Participation of the Ras signaling cascade in TGF-b1-induced IL-6 expression was further supported by observation that IL-6 expression is stimulated by oncogenic V12Ha-Ras in the absence or presence of TGF-b1. We also observed that TGF-b1 activates c-Jun mRNA expression through the Ras-Raf-MEK1 cascade, and transient expression of V12Ha-Ras stimulates c-Jun mRNA expression in the absence of TGF-b1. It TGF-b1-mediated IL-6 activation in human prostate cancer J-I Park et al was previously reported that TGF-b activates the c-Jun promoter through Smad3/Smad4-binding sites . However, TGF-b1-induced c-Jun mRNA expression was not suppressed by DN-Smads in both PC3 and DU145 cells, demonstrating that TGF-b1-induced, Ras-mediated activation of c-Jun gene expression is a Smad-independent phenomenon in prostate cancer cells. As expected, IL-6 induction by V12Ha-Ras transfection was strongly suppressed by the AP-1 inhibitor curcumin, supporting that contribution of the Ras-Raf-1-MEK1 signaling to TGF-b1-induced IL-6 expression largely depends on AP-1 activity in prostate cancer cells. Meanwhile, unlike mRNA expression, phosphorylation of c-Jun was not affected by the RasRaf-MEK1 signaling. This observation suggests that activation of JNK and other signaling pathways, which are involved in TGF-b1-induced c-Jun phosphorylation, are not controlled by the Ras signaling in prostate cancer cells. Alternatively, elevated expression of c-Jun mRNA by the Ras signaling may not significantly contribute to c-Jun phosphorylation, and IL-6 induction by the Ras-Raf-1-MEK1 cascade is associated with its activating effect on other factors, which enhance c-Jun and/or AP-1 activity. Further studies will be required to define the interrelation between the Ras-Raf-MEK1 and JNK-c-Jun-AP-1 signaling pathways in TGF-b1 activation of IL-6. Together, all these findings show that the Ras-Raf-1-MEK1 signaling cascade is activated by TGF-b1 and participates in the TGF-b1-induced IL-6 expression through an AP-1-dependent way in human prostate cancer cells. We have presented evidences that TGF-b1 activates the p38-NF-kB and Ras pathways in prostate cancer cells. Interestingly, a recent study demonstrated that oncogenic Ras enhances NF-kB transcriptional activity largely through a Raf-independent mechanism that utilizes a p38-dependent pathway (Norris and Baldwin, 1999) . This study also showed that the ability of Raf-1 to activate NF-kB is MEK1/Erk-dependent, but appears to require an autocrine pathway that ultimately utilizes the same p38-dependent mechanism as oncogenic Ras. It could be thus suspected that activation of the Ras pathway is prerequisite for p38-dependent NFkB activation in TGF-b1-treated prostate cancer cells. However, we observed that nuclear translocation of NFkB by TGF-b1 is not affected by PD98059, and blocking the Ras signaling cascade is less effective than blocking the p38-NF-kB signaling in inhibition of TGF-b1-induced IL-6 expression. This indicates that the RasRaf-1-MEK1 signaling does not play an important role in the p38-mediated NF-kB activation in TGF-b1-treated prostate cancer cells. It has been shown that Ras activates MAPK signaling cascades that most likely include the small GTP-binding protein Rac and the MEKK, PAK, and MKK4/SEK1 kinases. MKK4/ SEK1 can activate both the JNK and p38 (Troppmair et al., 1998) . Therefore, we cannot exclude the possibility that p38 and/or JNK are activated through other Rasactivated pathways, including Rac, PI3K, or MKK4/ SEK. Further studies will be required to define the possible crosstalks among MAPK cascades involved in TGF-b1-induced IL-6 expression.
The evidence we obtained here clearly show that in malignant prostate cancer cells, TGF-b1 activates IL-6 expression through a cooperation of multiple pathways including the Smad2, p38-NF-kB, JNK, and Ras. A possible synergistic collaboration between Smad2 and MAPK signaling was suggested by the observation that TGF-b1 activation of IL-6 is completely abrogated by cotransfection of DN-Smad2 and IkBDN, TAM-67, or N17Ha-Ras, whereas it is partially suppressed by individual transfection. Furthermore, IL-6 activation by WT-Smad2 transfection was severely inhibited by blocking the p38-NF-kB, SAPK/JNK, or Ras-Raf-MEK1 pathway, indicating that Smad2-induced IL-6 expression results from a cooperative interaction between the Smad2 and the MAPK pathways. Although the precise molecular mechanism of this synergism was not characterized in this study, our results imply that NF-kB and AP-1 are immediate effectors of TGF-b1 signaling, and Smad2 potentiates AP-1-and/or NF-kBdriven IL-6 gene expression (Figure 9 ). This is in line with previous reports that AP-1 and NF-kB are essential transcription factors for IL-6, and Smads potentiate AP-1-dependent gene transcription (Zhao and Young, 1996; Yingling et al., 1997; Berghe et al., 1999; Franchimont et al., 1999) . Besides AP-1 and NF-kB, several transcriptional factors including Sp1, C/EBP-b, and CREB have been known to be important in the regulation of IL-6 gene expression. Sp1 is a major transcription factor that is activated by TGF-b1, as in the case of a1 collagenase and p21 gene expression (Inagaki et al., 1994; Datto et al., 1995) . CBP is a coactivator that associates with AP-1, and potentiates gene transcription that is controlled by AP-1 consensus sites within promoter sequences (Horvai et al., 1997; StArnaud and Quelo, 1998) . It is therefore possible that TGF-b1 may increase Sp-1 or/and CBP activity, thereby 
TGF-b1-mediated IL-6 activation in human prostate cancer J-I Park et al leading to an increase in AP-1-or NF-kB-driven IL-6 gene transcription.
The human IL-6 promoter contains potential binding sites for a number of transcription factors, such as AP-1, CAAT enhancer-binding protein, and NF-kB, which is known to participate in the induction of IL-6 gene expression by various cytokines (Asschert et al., 1999; Berghe et al., 1999; Franchimont et al., 1999; Liberati et al., 1999) . In this context, activation of NF-kB and AP-1 and their essential role for the IL-6 induction in TGF-b1-treated prostate cancer cells leads to the conjecture that TGF-b1 stimulates interaction of these transcription factors with their cis-elements, which activates the transcriptional machinery leading to IL-6 mRNA synthesis. In addition, our finding that TGF-b1-induced IL-6 expression is strongly inhibited by actinomycin D supports that TGF-b1 activates IL-6 expression mainly at the transcriptional level. However, the steady-state levels of a particular mRNA depend not only on its synthesis but also on its rate of degradation. Interestingly, Sehgal and Thompson (1999) revealed that TGF-b1 induces the matrix metalloproteinase-9 (MMP-9) proenzyme in human prostate cancer cells through a protein synthesis-requiring process leading to increased MMP-9 mRNA stability. They also reported that TGF-b1 induces MMP-2 expression through increased stability of the secreted 72-kDa proenzyme with no evidence of either transcriptional activation or Figure 7 Involvement of the Ras-Raf-MEK1 pathway in IL-6 induction by TGF-b1. (a) Effect of various pharmacological inhibitors of signaling pathways on TGF-b1-induced IL-6 expression. PC3 and DU145 cells were preincubated with the PI3 K inhibitors wortmannin (100 nm) or LY294002, the Src inhibitor PP2 (10 mm), the PTK inhibitor Genistein (100 mm), and the MEK1 inhibitor PD98059 (50 mm) for 2 h before TGF-b1 treatment (2 ng/ml, 24 h). Secreted IL-6 protein level was determined using ELISA. (b) Induction of Erk1/2 phosphorylation by TGF-b1 and its regulation by the Ras signaling. PC3 cells were transfected with N17Ha-RasFlag, DN-Raf-1-V5, and V12Ha-Ras-Flag, and TGF-b1 (2 ng/ml) was treated for 1 h. Phosphorylation of Erk1/2 was examined by Western blot assay using a phospho-Erk1/2-specific antibody. Equal loading and expression of transfected genes were controlled by immunoblotting with anti-Flag-or anti-V5 antibody. (c) Participation of the Ras-Raf-MEK1 signaling in TGF-b1-induced IL-6 mRNA expression. PC3 cells transfected with N17Ha-Ras, DN-Raf-1, and V12Ha-Ras were treated with TGF-b1 (2 ng/ml, 24 h). IL-6 mRNA expression was analysed by Northern blot assay. (d) Involvement of the Ras-Raf-1-MEK1 cascade in TGF-b1-induced IL-6 protein expression. Expression of secreted IL-6 protein was determined using ELISA. Curcumin (10 mm) was added to cells for 2 h before TGF-b1 treatment (2 ng/ml, 24 h). Data represent means of triplicate assays. bars; standard deviations (e) Induction of c-Jun mRNA expression by TGF-b1 through the Ras signaling. PC3 cells transfected by N17Ha-Ras, DN-Raf-1, and V12Ha-Ras, or incubated with PD98059 were treated with TGF-b1 (2 ng/ml, 24 h). mRNA and protein expression of c-Jun and IL-6 were examined using semi-quantitative RT-PCR and Western blot analysis (WB), respectively ) were transfected with 2 mg of empty or expression plasmid using 8 ml of GenePOR-TER. For cotransfection, 2 mg of each plasmid was used and transfection efficiency was monitored using a fluorescence microscopy for GFP or CAT assay. The transfection efficiency was approximately 50-70% under our condition. (a) Suppression of TGF-b1-induced IL-6 protein expression by individual or cotransfection of DN-Smad2, IkBaDN, TAM-67, and N17Ha-Ras. Expression levels of secreted IL-6 protein were determined using ELISA. (b) Inhibition of WT-Smad2-induced IL-6 protein expression by blocking the p38-NF-kB, SAPK/JNK, and Ras cascade. The transfected cells were treated with TGF-b1 (2 ng/ml, 24 h) and expression of secreted IL-6 protein was determined using ELISA. Data represent means of triplicate assays. bars; standard deviations TGF-b1-mediated IL-6 activation in human prostate cancer J-I Park et al increased steady-state level of mRNA, demonstrating that TGF-b1 also regulates its target gene expression and activities through the nontranscriptional pathways. Consistent with this report, we observed that TGF-b1 treatment leads to a slight but detectable increase in IL-6 mRNA expression level in the presence of actinomycin D. A time course assay of mRNA decay showed that TGF-b1 enhances the stability of IL-6 mRNA in DU145 cells. These data thus indicate that TGF-b1 regulates IL-6 expression at both transcriptional and posttranscriptional levels in prostate cancer cells.
Modulation of RNA stability can have a significant impact on mRNA abundance and subsequent protein expression (Ross, 1995) . Although the mechanisms determining mRNA turnover are poorly understood, there has been growing interest in a particular pathway that regulates mRNA stability and is mediated by adenylate/uridylate (AU)-rich elements (AREs), usually found in the 3 0 -untranslated region of many short-lived mRNAs encoding proto-oncogenes, nuclear transcription factors, and cytokines (Chen and Shyu, 1995; Ross, 1996) . Recently, HuR, a member of the Elav family of RNA-binding protein, was identified as a potential trans-acting factor in ARE-containing mRNA stability, and its increased expression was found to lengthen mRNA half-lives and allow for enhanced mRNA translation of many growth factors associated with tumor progression such as VEGF and COX-2 Dixon et al., 2001; Brennan and Steite, 2001) . Although no systemic analysis has been carried out, our preliminary results showed that expression level of HuR is elevated in PC3 and DU145 cells following TGF-b1 treatment (data not shown). Intriguingly, it was recently demonstrated that HuR binds to ARE elements within the 3 0 untranslated region of IL-6 transcript . It is therefore conceivable that tumor-producing TGF-b1 enhances the mRNA stability of many tumor-promoting cytokines including IL-6 through a particular signal transduction pathway, which may be differentially modulated in tumor cells. In this ) were treated with increasing doses of TGF-b1 (0.5-5 ng/ml, 20 h) in the absence or presence of IL-6 nAb (2 mg/ml) and pulse-labeled for 4 h with 1 mCi/ml of [ 3 H]thymidine. The radioactivity incorporated into trichloroacetic acid-precipitable materials was counted by a liquid scintillation counter. (b) Effect of IL-6 on TGF-b1-induced apoptosis. PC3 and DU145 cells were treated with TGF-b1 (1, 2, and 5 ng/ml, 24 h) in the absence or presence of IL-6 nAb (2 mg/ml) and apoptotic cells were counted using tryphan blue exclusion assay. The data are the means and standard deviations of triplicate determinations TGF-b1-mediated IL-6 activation in human prostate cancer J-I Park et al context, it is already known that all three of the MAPK family members we investigated in this study play a role in the regulation of mRNA stability. Previous studies showed that in MDA-MB-231 breast cancer cells, p38 MAPK stabilizes urokinase-type plasminogen activator and its receptor mRNA in an ARE-dependent manner whereas IL-2 mRNA in Jurkat cells and IL-3 mRNA in PB-3c mast cells are destabilized through JNK inhibition (Chen et al., 1998; Ming et al., 1998; Montero and Nagamine, 1999) . Moreover, it was found that IL-6 mRNA is destabilized by p38 inhibition in human fibroblast-like synoviocytes, although the RNA sequence mediating this effect has not been characterized (Miyazawa et al., 1998) . It is noteworthy that in prostate cancer cells we analysed, TGF-b1-induced IL-6 mRNA expression is more severely prevented by p38 or JNK inhibitors compared to actinomycin D, raising the possibility that the p38 and/or JNK pathways also participate in the TGF-b1 regulation of IL-6 mRNA stability. We are now investigating whether the MAPK family members including p38, JNK, and Erk or other oncogenic signaling pathways are implicated in TGF-b1 activation of HuR in human prostate cancers. Elevated and autocrine production of IL-6 correlates with progression and metastasis of prostate cancer. Previous studies demonstrated that IL-6 is a protective resistance factor to prostate tumor cell killing by chemotherapeutic drugs such as cis-diamminedichloroplatinum and etoposide, and promotes anchorageindependent growth of immortalized, nontumorigenic prostate epithelial cells (Borsellino et al., 1995; Okamoto et al., 1998) . Recently, IL-6 was also suggested to stimulate tumor invasion and angiogenesis by induction of VEGF and MMPs (Cohen et al., 1996; Dankbar et al., 2000; Kossakowska et al., 1999) . However, the molecular mechanism by which IL-6 contributes to prostate tumor progression remains largely undefined. It was demonstrated that IL-6 is an autocrine growth factor for LNCaP human prostate cancer cells and the effect of IL-6 on prostate tumor cell growth is mediated through the JAK-STAT signaling pathway (Lou et al., 2000) . Qiu et al. (1998a) showed that IL-6 acts as one of the upstream inducers for c-erb-B-2 and activates the MAPK pathway in prostate cancer, indicating that MAPK activation occurs by multiple routes and contributes to prostate carcinogenesis. Therefore, it is likely that abundantly expressed TGF-b1, IL-6, and activated MAPK signaling cascades may act synergistically in actual prostate tumors. In the present study, we observed that inactivation of the IL-6 signaling by anti-IL-6 neutralizing antibody or antisense IL-6 results in the restoration of cellular sensitivity to TGF-b1-mediated growth arrest and apoptosis. Although we did not address the molecular mechanism of IL-6 action in the present work, our data strongly suggest that IL-6 might be one of the key oncogenic factors, whose activation renders tumor cells resistant to the TGF-b1's tumor suppression activity in malignant prostate carcinomas.
Taken together, the evidences we obtained here clearly demonstrate that TGF-b1 activates IL-6 expression in prostate carcinoma cells through a synergistic collaboration of multiple signaling pathways including Smad2, p38-NF-kB, SAPK/JNK, and Ras-Raf-MEK1. Our data also show that elevated IL-6 impinges on TGF-b1-induced growth arrest and apoptosis, suggesting that tumor suppression effect of TGF-b1, which is abnormally overexpressed in many advanced human cancers, might be attenuated or overcome through TGF-b1-mediated activation of IL-6. It is therefore conceivable that elevated IL-6 could play an essential role for the oncogenic switch of TGF-b1 function in the malignant progression of human tumors including prostate carcinoma.
Materials and methods
Cell lines and reagents
Human prostate carcinoma cell lines (LNCaP, PC3, DU145, and TSU-Pr1) analysed in this study were previously described (Chi et al., 1997) . The cells were maintained at 371C in RPMI-1640 medium supplemented with 10% fetal bovine serum (GIBCO BRL). The MEK1 inhibitor PD98059 was purchased from New England Biolabs Inc. The p38 MAPK inhibitors SB202190 and SB203580, the PI3 K inhibitors wortmannin and LY294002, the Src inhibitor PP2, and the PTK inhibitor Genistein, the AP-1 inhibitor Curcumin, and the proteasome inhibitor MG132 were purchased from Calbiochem. Porcine TGF-b1, anti-TGF-b neutralizing antibody, recombinant human IL-6, and monoclonal anti-human IL-6 antibody were obtained from R&D System. Actinomycin D and cyclohexamide were purchased from Sigma and added to cultures for 1 h before addition of TGF-b1.
Semiquantitative RT-PCR analysis
Total cellular RNA (1 mg) prepared by single-step method was reverse transcribed to cDNA using MoMuLV reverse transcriptase (GIBCO BRL) and random hexamer primers. For quantitative evaluation by RT-PCR, we initially performed the PCR reaction over a range of cycles (20-40 cycles), and 1 : 4 diluted cDNA (12.5 ng/50 ml PCR reaction) undergoing 24-36 cycles was observed to be within the logarithmic phase of amplification with all primers used for TGF-b1, TbR-I, TbR-II, IL-6, IL-6R, PAI-I, c-Jun and an endogenous expression standard gene GAPDH. Primer sequences are available upon request. The cDNA was then subjected to 28-34 cycles of PCR at 951C (1 min), 58-631C (0.5 min), and 721C (1 min) in 1.5 mm MgCl 2 -containing reaction buffer (PCR buffer II, Perkin Elmer). RT-PCR products (10 ml) were resolved on 2% agarose gels. Quantitation of gene expression levels was achieved by densitometric scanning of the ethidium bromidestained gels. Absolute area integrations of the curves representing each sample were then compared after adjustment for GAPDH expression. Integration and analysis were performed using Molecular Analyst software program (BioRad).
Northern blotting analysis
Total RNA (5 mg) was separated on formaldehyde-agarose gel. RNA was transfered to Nylon membrane using TurboBlotter (Scleicher & Schulell) and the membrane was baked in the CL-1000 UV crosslinker (UVP). Dioxigenin-labeled probes for IL-6, PAI-1, and GAPDH were prepared using PCR. Hybridization was conducted with Dig-labeled probes in the TGF-b1-mediated IL-6 activation in human prostate cancer J-I Park et al high SDS hybridization solution at 501C for 12 h. Detection was performed using DIG chemiluminescent detection kit (Roche) according to the manufacturer's protocol. The same blot was stripped and hybridized with Dig-labeled GAPDH probe.
IL-6 ELISA
The levels of IL-6 protein in the supernatant of cultured cells were quantitated using human ELISA system (Amersham Pharmacia Biotech), which is based on sandwich enzyme immunoassay technique. Briefly, 1 Â 10 4 cells were incubated in RPMI for 24 h and the supernatants were collected. Antibody (50 ml) to human IL-6 conjugated to biotin and 50 ml of the supernatant or IL-6 standard provided by the manufacturer were added to the well coated with an antibody against human IL-6. After incubation for 2 h at room temperature, streptavidin conjugated to horseradish peroxidase was added to each well with TMB substrate. The absorbance at 450 nm was determined using a microplate reader. 
Preparation of cytosolic and nuclear extracts
Nuclear and cytosolic extracts from TGF-b1-stimulated orunstimulated control cells were prepared for immunoblotting assay for NF-kB at the indicated time points. Cells were washed twice in ice-cold phosphate-buffered saline and harvested in 1 ml of phosphate-buffered saline with a rubber policeman. Samples were centrifuged for 1 min at 6000 g (41C), and the resulting cell pellets were resuspended in 100 ml of lowsalt buffer (20 mm HEPES, pH 7.9, 10 mm KCl, 0.1 mm NaVO 4 , 1mm EDTA, 1 mm EGTA, 0.2% Nonidet P-40, 10% glycerol, supplemented with a set of proteinase inhibitors, Complete TM ). After 10 min of incubation on ice, the samples were centrifuged at 13 000 g for 2 min (41C), and the supernatants (cytosolic extracts) were immediately frozen in a dry ice/ethanol bath. Pelleted nuclei were resuspended in 60 ml of high-salt buffer (20 mm HEPES, pH 7.9, 420 mm NaCl, 10 mm KCl, 0.1 mm NaVO 4 , 1mm EDTA, 1 mm EGTA, 20% glycerol, supplemented with Complete TM ), and nuclear proteins were extracted by shaking on ice for 30 min. Samples were centrifuged at 13 000 g for 10 min (41C), and the supernatants were taken as nuclear extracts. Purity of nuclear and cytoplasmic extracts was controlled by immunoblotting of U1 SnRNP 70 and b-tubulin, respectively.
Immunoblotting assay
Cells were lysed in a lysis buffer containing 20 mm Tris (pH 7.4), 150 mm NaCl, 1 mm EDTA, 1 mm EGTA, 1% Triton, 2.5 mm sodium phosphate, 1 mm b-glycerolphosphate, 1 mm Na 3 VO 4 , 1 mg/ml leupeptin, and 1 mm PMSF. The cell lysate was clarified by centrifugation and 20 mg of total protein was supplemented with Laemmli buffer and loaded on a 10% SDS-polyacrylamide gel for electrophoresis. Western analyses were performed using antibodies specific for NF-kB/p65, phospho-p38, phospho-c-Jun, phospho-Erk, and phsopho-ATF2 (SantaCruz Biotechnology). Antibody binding was detected by enhanced chemiluminescence (Amersham Pharmacia Biotech) using a secondary antibody conjugated to horseradish peroxidase. For stripping, the blots were incubated in a stripping buffer (0.2 m glycine pH 2.2, 0.1% SDS, 1% Tween-20) at 501C for 60 min.
DNA constructs and transfections
Expression plasmids encoding DN-Ha-Ras, DN-Raf-1, DNSmad2, and DN-Smad3 were described previously (Park et al., 2000) . DN-TbRII, WT-Smad2, WT-Smad3, and antisense IL-6 expression vectors were constructed by PCR using specific oligonucleotide primers (5 0 -GAAGGCGCCGTCCGTGCGC-TGGGGGCTC-3 0 and 5 0 -AACGCGGTAGCAGTAGAAGAT-3 0 for DN-TbRII; 5 0 -GAGGTTCGATACAAGAGGCTGT-3 0 and 5 0 -CATGGGACTTGATTGGTGAAGC-3 0 for WT-Smad2; 5 0 -CCATGTCGTCCATCCTGCCTTT-3 0 and 5 0 -TAAGA-CACACTGGAACAGCGGAT-3 0 for WT-Smad3; 5 0 -CCT-TCTCCACAAGCGCCTTC-3 0 and 5 0 -GGCAAGTCTCCT-CATTGAATC-3 0 for antisense IL-6). Primers for DN-TbRII were designed to generate a kinase domain-deficient mutant (codons 1-191). For construction of Flag-or V5-tagged expression vectors, the PCR products were first ligated to a linearized pCR2.1 vector (Invitrogen) and subsequently subcloned into pcDNA3.1 (pcDNA3.1-Flag-DNTbRII, pcDNA3.1-WTSmad2-V5, and pcDNA3.1-WTSmad3-V5). To create N-terminal Flag-tagged Smad2 construct, EcoRI fragments of pCR2.1 were subcloned into pCMVTaqII (Stratagene). Correct directionality and in-frame sequences in pCMVTaqII and pcDNA3.1 were verified using restriction mapping and DNA sequencing using Sequenase 2.0 (Amersham Pharmacia Biotech). TAM-67, the DN mutant of c-Jun, was provided by Birrer (National Cancer Institute, USA) (Brown et al., 1994) . The phosphorylation-defective IkBDN, which lacks the SR domain of IkB, was kindly provided by Ballard (Vanderbilt University, USA). This mutation inhibits degradation of IkB, rendering it a constitutively active molecule (Brockman et al., 1995) . pcDNA3-Flag-JBD, which encodes the SAPK/JNK binding domain of JIP-1 and thus interferes with c-Jun phosphorylation function of SAPK/JNK, was provided by Park (Dankook University, Seoul, Korea). Transfection of constructs was performed using GenePOR-TER (GTS) as described previously (Park et al., 2000) . Briefly, cells plated at a density of 2 Â 10 5 were incubated in the presence of 2 mg of empty or expression plasmid and 8 ml of GenePORTER. No detectable toxicity and apoptosis by reagents or vector were recognized. TGF-b1 was added with serum-free RPMI-1640 medium at 24 h after transfection. Each transfection experiment was carried out in triplicate. For cotransfection, 2 mg of each plasmid was used, thus total 4 mg of DNA was transfected for all transfection assay. The transfection efficiency was monitored using a fluorescence microscopy for GFP or CAT assay (Boehringer Mannheim) according to the instruction of manufacturer.
